Fundraising FoxBiotech Startups
11,077 companies tagged Biotech, with their investors and founders.
0 investors
Mitochon is an early-stage biopharmaceutical company developing therapeutics. The page does not provide details about specific products, target indications, or customer segments beyond the biopharmaceutical sector.
0 investors
0 investors
MitoSense develops Mitochondria Organelle Transplantation (MOT) technology, a cellular biotherapy that uses mitochondria to treat neurodegenerative diseases such as ALS, Parkinson's, and Alzheimer's. The company holds an exclusive license to the MOT technology and is developing it as a cell therapy.
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
Moleculin Biotech is a Phase 3 clinical-stage biopharmaceutical company developing therapeutic candidates for hard-to-treat tumors and viruses, with a lead program (Annamycin) targeting relapsed or refractory acute myeloid leukemia and soft tissue sarcoma.
0 investors
Moleculin Biotech is a pharmaceutical development company conducting late-stage clinical trials of Annamycin (naxtarubicin), a next-generation anthracycline chemotherapy designed to treat relapsed/refractory acute myeloid leukemia and other cancers with reduced cardiotoxicity compared to conventional anthracyclines. The company also maintains two additional drug portfolios targeting hard-to-treat cancers and viruses, with clinical and preclinical programs supported through academic partnerships and investigator-initiated trials.
0 investors
0 investors
Mongoose Bio is a company focused on T-cell therapies for cancer, drawing on research into antigen-specific CD8+ T cells, IL-21 priming, and adoptive cell transfer for tumors such as melanoma and Merkel cell carcinoma.
0 investors
Monopar Therapeutics is a clinical-stage biotechnology company developing radiopharmaceuticals for oncology and a treatment for Wilson Disease, a rare genetic disorder. Its pipeline includes radiopharmaceutical candidates targeting advanced solid tumors (MNPR-101-Zr for imaging, MNPR-101-Lu and MNPR-101-Ac for therapy) and the late-stage Wilson Disease drug ALXN1840.
0 investors
0 investors
Morphoceuticals is a TechBio company mapping the "bioelectrome" — the body's cellular communication networks that govern tissue repair and organ regeneration. It combines multi-omics, bioelectric profiling, and AI to modulate ion channels for applications in regenerative medicine.
0 investors
0 investors
Most Cardio develops cardiovascular surgical instrumentation using a reposable design platform (reusable handles with disposable end effectors) combined with micro-robotics and nanotechnology to emulsify and remove arterial plaque via minimally invasive procedures. Its products, including a robotic control station, catheters, micro-emulsifiers, extractor wires and MIS access ports, target clinicians at hospitals and surgery centers as alternatives to stents, angioplasty and heart bypass surgery.
0 investors
0 investors
0 investors
Mulberry Biotherapeutics develops bacteria-mediated immunotherapies using genetically engineered, live-attenuated Salmonella Typhimurium injected directly into tumors to treat rare, slow-growing tumors. Its lead program, MUL001, targets Neurofibromatosis type 2-related schwannomatosis (NF2-SWN), with planned follow-on indications including NF1-associated nerve sheath tumors and meningiomas.
0 investors